NASDAQ · Medical Devices · USD

Bluejay Diagnostics, Inc. (BJDX) Stock Analysis

Bluejay Diagnostics, Inc. (BJDX) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

BJDX

$0.83

−$0.02 (−2.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BJDX with… →

BJDX Key Statistics

As of Sep 4, 2026

Trading

Open: $0.84
Previous Close: $0.85
Day's Range: 0.82–0.85
52-Week Range: 0.82–16.68
Volume: 89.00K
Beta: 0.91

Valuation

Market Cap: $861.30K
P/E Ratio: unprofitable
EPS (ttm): −2.21

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$6.85M
Profit margin: 0.00%
Shares Outstanding: 1.03M
1-Year Return: −85.25%

Dividend and dates

Avg Volume: 4.86M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BJDX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−51.88%−85.16%−83.95%−99.00%−86.30%−68.82%

2021*20222023202420252026*

Year	Return
2026 (partial year)	−68.82%
2025	−86.30%
2024	−99.00%
2023	−83.95%
2022	−85.16%
2021 (partial year)	−51.88%

As of September 4, 2026.

BJDX Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$6.85M	—
2024	$0.00	−$7.72M	—
2023	$0.00	−$9.95M	—
2022	$249.04K	−$9.30M	−3733.1%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$6.95M	−$6.85M	—
2024	$0.00	—	−$7.17M	−$7.72M	—
2023	$0.00	$0.00	−$10.31M	−$9.95M	—
2022	$249.04K	$48.91K	−$9.32M	−$9.30M	−3733.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BJDX Valuation vs Medical Devices Median

Median of 151 stocks

Metric	BJDX	Medical Devices median	vs median
Profit margin	0.00%	−1.69%	1.7 pts above

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values Bluejay Diagnostics, Inc. (BJDX) at $861.30K. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 6.

The most recent close on file for BJDX is $0.83, dated September 4, 2026. That is −$0.02 (−2.00%) against the previous close. Over the past 52 weeks the price has ranged from $0.82 to $16.68. The latest close sits 1.71% above that 52-week low.

Financial Health

In fiscal 2025, Bluejay Diagnostics, Inc. reported revenue of $0.00. The same year closed with a net loss of $6.85M. The reported profit margin is 0%. That is 1.7 percentage points above the Medical Devices median of −1.69%. Trailing earnings per share are −2.21.

Across the 4 fiscal years on file, revenue moves from $249.04K in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 0.91. Annualized volatility over the trailing 4 years is 169.39%. Over the trailing twelve months the price has returned −85.25%. Across 3 years the annualized return works out at −95.48%.

Growth & Income

No dividend is on file for BJDX.

So far in 2026 the price is −68.82%. The strongest complete calendar year on file is 2023 at −83.95%; the weakest is 2024 at −99.00%. Of the 4 complete calendar years on file, 0 finished higher.

Peer Comparison

Bluejay Diagnostics, Inc. (BJDX) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Bluejay Diagnostics, Inc.	BJDX	$861.30K	—
Abbott Laboratories	ABT	$187.45B	35.1
Medtronic plc.	MDT	$120.46B	22.9
Stryker Corporation	SYK	$116.27B	31.9

The Medical Devices industry average P/E ratio is 26.8x. Bluejay Diagnostics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

MDT

Medtronic plc.

$120.46B

SYK

Stryker Corporation

$116.27B

BSX

Boston Scientific Corporation

$69.27B

Edwards Lifesciences Corporation

$51.82B

DXCM

DexCom, Inc.

$33.17B

View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Visit website →